600511 Overzicht aandelen
China National Medicines Corporation Ltd. distribueert samen met haar dochterondernemingen farmaceutische producten in China.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 5/6 |
Beloningen
Risicoanalyse
China National Medicines Corporation Ltd. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | CN¥31.84 |
| 52 Week Hoogtepunt | CN¥38.00 |
| 52 Week Laag | CN¥27.12 |
| Bèta | 0.45 |
| 11 maand verandering | -7.84% |
| 3 maanden verandering | -5.80% |
| 1 Jaar Verandering | 11.25% |
| 33 jaar verandering | 6.28% |
| 5 jaar verandering | 26.45% |
| Verandering sinds IPO | 892.42% |
Recent nieuws en updates
The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 25
China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares
Sep 26Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)
Sep 10Recent updates
The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 25China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares
Sep 26Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)
Sep 10Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture
Jul 28China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement
Jun 24China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854
Jun 07Is China National Medicines (SHSE:600511) Using Too Much Debt?
Jun 05Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)
May 21Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal
Apr 10China National Medicines (SHSE:600511) Could Easily Take On More Debt
Feb 28Rendement voor aandeelhouders
| 600511 | CN Healthcare | CN Markt | |
|---|---|---|---|
| 7D | 0.1% | -3.4% | -1.2% |
| 1Y | 11.3% | -19.0% | 3.1% |
Rendement versus industrie: 600511 exceeded the CN Healthcare industry which returned -19% over the past year.
Rendement versus markt: 600511 exceeded the CN Market which returned 3.1% over the past year.
Prijsvolatiliteit
| 600511 volatility | |
|---|---|
| 600511 Average Weekly Movement | 5.5% |
| Healthcare Industry Average Movement | 7.8% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.4% |
Stabiele aandelenkoers: 600511 has not had significant price volatility in the past 3 months compared to the CN market.
Volatiliteit in de loop van de tijd: 600511's weekly volatility (5%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1999 | 3,138 | Guotao Tian | www.cncm.com.cn |
China National Medicines Corporation Ltd. distribueert samen met zijn dochterondernemingen farmaceutische producten in China. Het bedrijf produceert en verkoopt ook nieuwe medicijnen en afgewerkte medicijnen; verkoopt Chinese patentmedicijnen en westerse medicijnen en medische apparatuur; en biedt opslag en import- en exportagentdiensten.
China National Medicines Corporation Ltd. Samenvatting
| 600511 fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | CN¥24.02b |
| Inkomsten(TTM) | CN¥2.16b |
| Inkomsten(TTM) | CN¥51.19b |
11.1x
Koers/Winstverhouding0.5x
P/S-verhoudingIs 600511 overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| 600511 resultatenrekening (TTM) | |
|---|---|
| Inkomsten | CN¥51.19b |
| Kosten van inkomsten | CN¥47.36b |
| Brutowinst | CN¥3.83b |
| Overige uitgaven | CN¥1.67b |
| Inkomsten | CN¥2.16b |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 2.87 |
| Brutomarge | 7.49% |
| Nettowinstmarge | 4.23% |
| Schuld/Eigen Vermogen Verhouding | 1.5% |
Hoe presteerde 600511 op de lange termijn?
Bekijk historische prestaties en vergelijking